Steven AR Murphy: Urolithin A Shows Immune Rejuvenation and Mitochondrial Benefits in New Trial
Steven AR Murphy, Medical Director, Concierge Medical Associates, shared a post on LinkedIn:
”A Change in Urolithin A Dosing: What the Latest Human Data Means for Longevity Medicine
For years, Urolithin A has intrigued longevity researchers as a gut-derived molecule capable of activating mitophagy, the process of recycling worn-out mitochondria. In essence, it’s cellular housekeeping: clearing broken power plants so new ones can thrive.
Many of our patients take this for it’s Mitophagy benefit.
A newly published Nature Aging randomized, placebo-controlled trial has now brought real human evidence to the table. In just 28 days, healthy adults aged 45–70 who took 1,000 mg of Urolithin A daily showed clear biologic signs of immune rejuvenation and improved mitochondrial metabolism—with excellent safety.
Here’s what changed:
T cells looked and acted younger, with more naive-like CD8 cells and lower exhaustion markers.
Immune metabolism rewired, favoring fatty acid and amino acid oxidation (a signature of healthier, more resilient immunity).
Mitochondrial programs activated, including upregulation of PGC-1α, the master regulator of energy biogenesis.
From a clinical perspective, the data justify what we’re now implementing at Concierge Medical Associates.
While the study didn’t include a 500 mg arm, 1,000 mg is the only dose shown to move the biological levers of aging in humans.
If your goal is to enhance mitochondrial resilience, immune performance, and long-term vitality, this represents a practice-changing moment in longevity medicine and you can read my full analysis—including how I’m adjusting protocols—in the latest Longevity Insider with Dr. Murphy post here.”
Stay updated with Hemostasis Today.
-
May 25, 2026, 11:20Abdul Mannan: Why Thalassaemia Is More Than Low Haemoglobin
-
May 25, 2026, 11:06Roberta Gualtierotti: Iron Is More Than a Hematologic Parameter
-
May 25, 2026, 11:03Divyaswathi Citla Sridhar: How Bone Health Is Impacted in Bleeding Disorders
-
May 25, 2026, 10:48Ama Ameyaw: Beginning My Research Journey in HIT and Platelet Immunology at the Wen Lab
-
May 25, 2026, 10:46Fredrick Chalinga: Negative DAT Does Not Mean No Hemolysis
-
May 25, 2026, 10:41Mukaram Rana: Anticoagulation-Free VV-ECMO for Trauma-Induced Pulmonary Haemorrhage in Fontan Physiology
-
May 25, 2026, 10:30Rob Mac Sweeney: Prevention and Treatment of Thrombosis in Patients With Decompensated Cirrhosis
-
May 25, 2026, 07:34Wolfgang Miesbach: The Maastricht Bleeding Cohort and The High Prevalence of BDUC in Women
-
May 25, 2026, 07:31Maya Brown-Zimmerman: Bridging Patient Experience and Genetic Counseling in Marfan Syndrome